OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
πΊπΈUnited States
A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2015-10-20
- Target Recruit Count
- 45
- Registration Number
- NCT01299454
- Locations
- πΊπΈ
Study Site, San Antonio, Texas, United States
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2015-10-29
- Target Recruit Count
- 19
- Registration Number
- NCT01289080
- Locations
- πΊπΈ
Otsuka Investigational Site, Minneapolis, Minnesota, United States
Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 23514
- Registration Number
- NCT01284218
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3
Terminated
- Conditions
- HyponatremiaInappropriate ADH SyndromeDilutional Hyponatremia
- Interventions
- Other: Fluid Restriction
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2014-10-30
- Target Recruit Count
- 124
- Registration Number
- NCT01227512
- Locations
- πΊπΈ
Otuska Investigational Site, Orange, California, United States
πΊπΈOtsuka Investigational Site, Madison, Wisconsin, United States
Tolvaptan Extension Study in Participants With ADPKD
Phase 3
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2021-10-25
- Target Recruit Count
- 1083
- Registration Number
- NCT01214421
- Locations
- π¬π§
Otsuka Investigational Site, Swansea, United Kingdom
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Phase 2
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2018-06-14
- Target Recruit Count
- 25
- Registration Number
- NCT01210560
- Locations
- πΊπΈ
Mayo Medical Center, Rochester, Minnesota, United States
πΊπΈDavita Clinical Research, Minneapolis, Minnesota, United States
πΊπΈTufts-New England Medical Center, Boston, Massachusetts, United States
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2015-04-02
- Target Recruit Count
- 252
- Registration Number
- NCT01149655
- Locations
- π¨π³
Study Site, Taoyuan County, Taiwan
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 501
- Registration Number
- NCT01145313
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 48865
- Registration Number
- NCT01141400
Outcomes in MEasurement-Based Treatment
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 914
- Registration Number
- NCT01141387
Β© Copyright 2025. All Rights Reserved by MedPath